Gritstone bio Inc (GRTS)

[jondoeuk]

The company will webcast an investor event with its executive management team on Friday the 8th, from 6:00-8:00 p.m. ET.

The event will focus on the company's clinical-stage immunotherapies, GRANITE (personalised) and SLATE (shared neoantigens), including an overview of the ongoing trials as well as the type of preliminary immunogenicity and safety data the company expects to have for presentation at the European Society for Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) in Dec*. The studies are on-track for completion in 2020 with data expected in mid-2020. The company will also review the novel shared neoantigens contained within its first SLATE product candidate that will be presented at the SITC Conference earlier that day.

A live webcast will be available within the Investors & Media section of the website at https://ir.gritstoneoncology.com/investors/events An archived replay will be accessible for 30 days following the event.

* (Mini Oral session) 93O - First Results of Phase 1/2 Studies Evaluating Viral Vector-based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T-Cell Responses in Patients with Advanced Cancers